MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer
The chemotherapy-free combination of tucatinib and trastuzumab shrank tumours in almost four in ten patients with previously treated HER2-positive colorectal cancer, with responses lasting about a year, and became the first approved HER2 regimen for the disease.
Overview
Phase 2 study of 117 patients with HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer previously treated with chemotherapy, of whom 84 received tucatinib plus trastuzumab.
Objective response was 38.1 percent with a median duration of response of 12.4 months, median progression-free survival 8.2 months and median overall survival 24.1 months; tucatinib alone was less active and patients crossed over to the combination.
- Objective response 38.1 percent; median duration of response 12.4 months.
- Median overall survival 24.1 months.
HER2 amplification testing is now standard in RAS wild-type metastatic colorectal cancer, and tucatinib-trastuzumab is the approved chemotherapy-free option after first-line therapy.
- Single-arm study in a RAS wild-type population; activity in RAS-mutant tumours is not expected.
- Confirmatory first-line trial (MOUNTAINEER-03) ongoing.
Similar pages
not linked directly; found by shared links- Key paperDESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer
Shares HER2-amplified colorectal cancer, The Lancet Oncology, Trastuzumab.
- Key paperHERACLES: trastuzumab and lapatinib in HER2-amplified, KRAS wild-type metastatic colorectal cancer
Shares HER2-amplified colorectal cancer, The Lancet Oncology, Trastuzumab.
- TrialTL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer
- TrialTucatinib+Trastuzumab+Eribulin in HER2+ MBC
Shares Tucatinib, Trastuzumab.
- TrialA Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Shares Tucatinib, Trastuzumab.
- TrialHER2CLIMB-05
Shares Tucatinib, Trastuzumab.
- Key paperHER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases
Shares Tucatinib, Trastuzumab.
- Key paperHER2CLIMB brain metastases analysis: intracranial efficacy and survival with tucatinib
Shares Tucatinib, Trastuzumab.